Approximately 50% of bladder cancers harbor FGFR genetic alterations; 75% of the NMIBC and approximately 15% of high-grade invasive urothelial cancers harbor FGFR3 genetic alterations, and 2% of urothelial cancers carry FGFR2 mutations [6]. This evidence concerns the gene FGFR3 and urinary bladder cancer.